Abstract

The present invention relates to a reverse micelle drug delivery system and an oral pharmaceutical composition comprising same, the system having a 2-phase mixed solution, which comprises a fatty acid acylated GLP-1 agonist, bile salts, a non-ionic surfactant and a polar solvent-non-polar solvent, wherein the fatty acid acylated GLP-1 agonist binds to bile acids and is encapsulated in reverse micelles, and the zeta potential of the reverse micelles is -10 to 10 mV. According to the present invention, the reverse micelle drug delivery system according to the present invention can easily transport the fatty acid acylated GLP-1 agonist through ASBT of intestinal cells by stably encapsulating the fatty acid acylated GLP-1 agonist inside reverse micelles and exposing bile acid derivatives bound to the fatty acid acylated GLP-1 agonist to the surface of the reverse micelles, and can improve the oral bioavailability of a drug if the drug delivery system is used through an oral pharmaceutical composition.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 38/26 - Glucagons
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present disclosure relates to a cell-penetrating peptide, an anticancer peptide, and a pharmaceutical composition for preventing or treating cancer including the same. The cell-penetrating peptide of the present disclosure can further improve a cancer cell growth inhibitory effect of anticancer peptides, especially cancer therapeutic peptides with improved anticancer activity by cyclic structures, and thus can be effectively applied to the prevention or treatment of various cancers.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present invention relates to an oral pharmaceutical composition for the prevention and treatment of osteoporosis, comprising an ion-bonded complex consisting of teriparatide, L-lysine-linked deoxycholic acid, deoxycholic acid, and an alkylglycoside type surfactant. With a micelle structure having teriparatide integrated thereinto, the ion-bonded complex containing teriparatide according to the present invention is restrained from being degraded by peptidases the gastrointestinal tract, thus being able to maintain a high dose of the drug and can take advantage of various transmembrane absorption pathways to improve the permeability of the drug, with the ultimate increase of oral bioavailability of the drug teriparatide.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The present invention relates to a complex of a lipid nanoparticle and a novel cell-penetrating peptide, and, more specifically, to a complex comprising a lipid nanoparticle and a novel peptide having better cell-penetrating property than common TAT peptides. The complex can effectively penetrate into cells, tissues, blood and the like of a living body.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to a complex including a cell-permeable peptide and a glucagon-like peptide-1 (GLP-1) receptor agonist and, more specifically, to a complex including: a cell-permeable peptide exhibiting improved cell permeability compared to commercially available TAT peptide; and a glucagon-like peptide-1 agonist. The complex including a cell-permeable peptide and a GLP-1 receptor agonist according to the present invention improves the permeability of the GLP-1 receptor agonist into cell membranes, thus making it possible to administer drugs in a non-invasive manner or to effectively deliver drugs into the body, such as cells, tissues, blood, etc.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/605 - Glucagons
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 38/26 - Glucagons
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Proposed is a pharmaceutical composition for oral administration, the composition including an ionic bond complex composed of teriparatide, deoxycholic acid, Nα-deoxycholyl-L-lysyl-methylester (DCK), and di-alpha-tocopherol polyethylene glycol 1000 succinate, and a method for preparing the same is also proposed. The oral pharmaceutical composition is useful for the treatment of osteoporosis because the pharmaceutical composition can increase intestinal membrane permeability and oral administration bioavailability of teriparatide and improve patient compliance.

IPC Classes  ?

• A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

The present invention relates to a cell-penetrating peptide, an anti-cancer peptide, and a pharmaceutical composition for preventing or treating cancer, comprising same. The cell-penetrating peptide of the present invention can further improve cancer cell proliferation inhibitory effects of an anti-cancer peptide, especially, a cancer therapeutic peptide having improved anti-cancer activity by means of a ring structure, and thus can be effectively used in the prevention or treatment of various types of cancer.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a novel peptide having cell-penetrating ability, and more specifically, to a cell-penetrating peptide exhibiting improved cell-penetrating ability compared to a commercially available TAT peptide. The novel cell-penetrating peptide of the present invention can effectively enter a living organism such as cells, tissues, blood, and the like.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided are an oral delivery composition including oxaliplatin, a water-soluble anticancer agent, and a preparation method thereof, including forming an ionic complex with a bile acid derivative, which is an oral absorption promoter, and oxaliplatin, and incorporating it into the inner aqueous phase of a water-in-oil-in-water (w/o/w) multiple nanoemulsions, thereby obtaining the oral delivery composition with improved oral bioavailability of oxaliplatin, a water-soluble anticancer agent, avoiding the inconvenience and problems of injection, improving patient compliance, and reducing medical costs.

IPC Classes  ?

• A61K 31/282 - Platinum compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• A61K 31/12 - Ketones
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention relates to an oral pharmaceutical composition containing pemetrexed as a water-soluble anticancer drug and a method of manufacturing the same, and more particularly to an oral pharmaceutical composition, in which an ion-binding complex of pemetrexed and a bile acid derivative as an oral absorption enhancer is formed, mixed with a pharmaceutical additive, and then provided in the form of a capsule or a tablet through pressing or included in the internal water phase of a w/o/w (water-in-oil-in-water) multiple nanoemulsion, thus increasing the oral bioavailability of pemetrexed as the water-soluble anticancer drug, whereby pemetrexed, which is currently administered only in the form of an injection formulation, can be manufactured into a formulation capable of being orally administered, ultimately alleviating inconvenience and problems with use of injection formulations, improving patient compliance and contributing to a reduction in medical expenses.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/113 - Multiple emulsions, e.g. oil-in-water-in-oil
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

The present invention relates to an oral pharmaceutical composition comprising an ion-bonding complex consisting of teriparatide, deoxycholic acid, Nα-deoxycholyl-L-lysyl-methylester (DCK) and D-α-tocopherol polyethylene glycol 1000 succinate, and a method for preparing same. As the oral pharmaceutical composition according to the present invention can increase intestinal membrane permeability and oral administration bioavailability of teriparatide and improve patient compliance, the oral pharmaceutical composition is useful for treating osteoporosis.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/107 - Emulsions
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

The present invention relates to a protein carrier, a recombinant protein in which the translocation regions of botulinum toxin light chain and heavy chain are fused, and a composition comprising same, in order to enhance the effects and cell penetration of a botulinum toxin. Particularly, the present invention relates to a cosmetic composition comprising the fusion protein and a transdermal absorption accelerator.

IPC Classes  ?

• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/37 - Esters of carboxylic acids
• A61K 8/34 - Alcohols
• A61Q 19/08 - Anti-ageing preparations

Abstract

Disclosed are a translationally controlled tumor protein derived-protein transduction domain (TCTP-PTD) having the ability to penetrate the cell membrane, and to the use thereof. The TCTP-PTD peptide is capable of improving the ability of a target substance to penetrate the cell membrane to thereby effectively deliver the target substance into a living body, including cells, tissue and blood. Thus, the TCTP-PTD peptide may be used for research purposes in vitro, and may be used for clinical purposes, including treatment of various diseases, delivery of contrast agents, etc., and may also be used for diagnostic purposes and in cosmetic applications.

IPC Classes  ?

• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin